HIV patients may ditch one pill: Single-Drug therapy holds promise in new trial
NCT ID NCT00421551
First seen Apr 08, 2026 · Last updated May 09, 2026 · Updated 2 times
Summary
This study tested whether HIV patients with long-term viral suppression could switch to a single drug (darunavir/r) instead of the standard two-drug regimen. 225 participants were followed for 48 weeks to see if the single drug could keep the virus undetectable. The goal was to simplify treatment without losing effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service des maladies infectieuses et tropicales Hopital Pitie salpetriere
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.